1. Home >
  2. Recipharm Acquires Consort Medical

M&A Deal Summary

Recipharm Acquires Consort Medical

On December 6, 2019, Recipharm acquired medical products company Consort Medical

Acquisition Highlights
  • This is Recipharm’s 6th transaction in the Medical Products sector.
  • This is Recipharm’s 3rd transaction in the United Kingdom.

M&A Deal Summary
Date 2019-12-06
Target Consort Medical
Sector Medical Products
Buyer(s) Recipharm
Deal Type Add-on Acquisition

Target

Consort Medical

Hemel Hempstead, United Kingdom
Consort Medical plc designs, develops, manufactures, and sells specialty medical drug delivery devices and services to the pharmaceutical industry in Europe, the United Kingdom, the United States, and internationally. Consort Medical was founded in 1946 and is based in Hemel Hempstead, the United Kingdom.

Search 204,717 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Recipharm

Stockholm, Sweden
Category Company
Founded 1995
Sector Life Science
Employees7,383
DESCRIPTION

Recipharm is a global Pharma CDMO providing a full-service offering to leading Pharmaceutical companies and Biotechs globally. Recipharm was founded in 1995 and is based in Stockholm, Sweden.

DEAL STATS #
Overall 16 of 18
Sector (Medical Products) 6 of 6
Type (Add-on Acquisition) 7 of 9
Country (United Kingdom) 3 of 3
Year (2019) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-01 Sanofi SA - Inhalation Contract Manufacturing Business

Paris, France

Sanofi SA - Inhalation Contract Manufacturing Business which includes development and manufacturing capabilities for novel respiratory products. Business including a manufacturing facility located in Holmes Chapel, UK.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-10-01 Lusomedicamenta Sociedade Técnica Farmacêutica S.A.

Jordbro, Sweden

Lusomedicamenta Sociedade Técnica Farmacêutica, S.A. focuses on cardiovascular disease, respiratory diseases and metabolic diseases.

Sell €26M
Mergr

Product

Company

Legal